Streetbeat News

Stock Prices

TFX

Stephens analyst George Sellers has reiterated an Overweight rating on Teleflex Incorporated (NYSE:TFX), raising the price target to $315 from $305. The analyst praised Teleflex's strong market position in the interventional urology specialty and expects the company to successfully grab a share in the rectal spacer market. Teleflex's recent acquisition of Palette Life Sciences for $600 million is expected to bolster its growth profile. However, TFX shares are currently trading lower by 2.25%.

Portfolio Pulse from Nabaparna Bhattacharya

July 27, 2023 | 7:29 pm

MRSN

Mersana Therapeutics announced that the UPLIFT clinical trial of upifitamab rilsodotin did not meet its primary endpoint, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:28 pm

BAX

Baxter International reported lower-than-expected revenue results and issued Q3 and FY23 adjusted EPS guidance, leading to a drop in its share price.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:28 pm

AAPL

DIS

Disney CEO Bob Iger's recent comments have led to speculation of a potential asset sale, causing Disney's stock price to drop to COVID-19 lows. Analysts believe Iger is considering selling some of Disney's assets, including ESPN's transition to streaming. Apple's Tim Cook is considered a likely buyer. The ongoing Hollywood writers and actors strike could disrupt a potential sale.

Portfolio Pulse from Piero Cingari

July 27, 2023 | 7:28 pm

SHOO

Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on Steven Madden Ltd (NASDAQ:SHOO) with a price target of $39. The company is expected to report Q2 2023 results on August 2, 2023. The analyst expects a Q2 EPS of $0.48, down from $0.63 last year, and total sales to decrease 12.5% Y/Y to $468 million. Despite volatile macro conditions, the analyst believes SHOO's wholesale channel trends can improve through the year.

Portfolio Pulse from Shivani Kumaresan

July 27, 2023 | 7:27 pm

TALK

Talkspace reported better-than-expected Q2 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:27 pm

CTCX

Carmell Therapeutics has announced a merger with Axoloti Biologix, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:26 pm

URGN

UroGen Pharma announced positive topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:26 pm

ULBI

Ultralife Corporation reported better-than-expected Q2 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:25 pm

FTNT

Unusual options activity has been observed for Fortinet (NASDAQ:FTNT), with a large position indicating a bullish stance. The sentiment among these big-money traders is split 50% bullish and 50% bearish. The price target for Fortinet over the last 3 months, based on volume and open interest, ranges from $70.0 to $80.0. Several financial institutions, including Goldman Sachs, Rosenblatt, Baird, Morgan Stanley, and Barclays, have maintained their positive ratings on Fortinet.

Portfolio Pulse from Benzinga Insights

July 27, 2023 | 7:17 pm